Barry A Singer, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold, Mark Gudesblatt, Elzbieta Jasinska, Christopher C LaGanke, Robert T Naismith, Donald Negroski, Jiwon Oh, Miguel Angel Hernandez Perez, Krzysztof Selmaj, Florian Then Bergh, Annette Wundes, Tjalf Ziemssen, Wanda Castro-Borrero, Hailu Chen, Seth Levin, Matthew Scaramozza, Sai L Shankar, Ting Wang, Sibyl Wray
BACKGROUND: Diroximel fumarate (DRF) is approved for adults with relapsing-remitting multiple sclerosis (RRMS) in Europe and for relapsing forms of MS in the United States. DRF and dimethyl fumarate (DMF) yield bioequivalent exposure of the active metabolite monomethyl fumarate. Prior studies indicated fewer gastrointestinal (GI)-related adverse events (AEs) with DRF compared with DMF. OBJECTIVE: To report final outcomes from EVOLVE-MS-1. METHODS: EVOLVE-MS-1 was an open-label, 96-week, phase 3 study assessing DRF safety, tolerability, and efficacy in patients with RRMS...
October 31, 2023: Multiple Sclerosis: Clinical and Laboratory Research